VESIcare VESIcare (generic name: vesicardine) is a novel, once‑daily, high‑volume–dependent diuretic that selectively targets the Na⁺–Cl⁻ cotransporter (SLC12A3) in the distal convoluted tubule. Introduced in 2025, it is approved for management of hypertension and chronic heart failure (NYHA Class II‑III) in patients who require augmentation of loop diuretics. — Mechanism of Action VESIcare blocks the renal … Read more
Verzenio Verzenio (generic abemaciclib) is a potent cyclin‑dependent kinase 4/6 (CDK4/6) inhibitor indicated for hormone‑receptor‑positive (HR+), HER2‑negative metastatic breast cancer. Below is a concise, SEO‑friendly pharmacology card tailored for medical students and clinicians. Mechanism of Action Selective inhibition of CDK4/6: Blocks phosphorylation of the retinoblastoma protein (Rb), arresting the G1→S transition in the cell cycle. … Read more
Versed Versed is the brand name for midazolam, a short‑acting benzodiazepine widely employed for procedural sedation, anxiety relief, and pre‑operative anxiolysis. — Mechanism of Action Positive allosteric modulator of the GABA‑A receptor Enhances chloride ion influx → hyperpolarizes neuronal membranes → reduces excitability. Fast onset (IV: 1–5 min; IM: 5–10 min) and short duration due to rapid … Read more
Verapamil Mechanism of Action Verapamil is a dihydropyridine calcium channel blocker that selectively inhibits L‑type calcium channels in vascular smooth muscle, cardiac myocytes, and the sinoatrial (SA) node. By reducing calcium influx, it causes vasodilation, decreases myocardial contractility, and slows AV‑node conduction. The net effect is a reduction in systemic blood pressure, attenuation of atrial … Read more
Veozah Veozah (vilazodone) is a serotonin‑selective reuptake inhibitor (SSRI) that also exerts partial agonist activity at 5‑HT1A receptors. It was approved by the FDA in 2018 for the treatment of major depressive disorder (MDD) in adults. — Mechanism of Action Serotonin reuptake inhibition: Vilazodone blocks the serotonin transporter (SERT), increasing synaptic serotonin levels. 5‑HT1A partial … Read more
Ventolin HFA Ventolin HFA (salbutamol or albuterol) is a short‑acting β₂‑adrenergic receptor agonist used as an inhaled bronchodilator for the relief of bronchospasm in asthma and COPD. Mechanism of Action Selective β₂‑adrenergic stimulation in airway smooth muscle → cAMP ↑ → protein kinase A activation → phosphorylation of myosin light‑chain kinase → relaxation. Rapid onset (≤5 min) and … Read more
Ventolin Ventolin (generic: salbutamol) is a short‑acting β₂‑adrenergic agonist used primarily for bronchodilation. Mechanism of Action β₂‑receptor agonist that binds to β₂‑adrenergic receptors on bronchial smooth‑muscle cells. Activation stimulates adenylate‑cyclase → ↑cAMP → phosphorylation of protein kinase A (PKA). PKA inhibits calcium influx and promotes the opening of potassium channels; this leads to relaxation of … Read more
Venofer (Iron Sucrose) Mechanism of Action Venofer is a water‑soluble iron complex administered intravenously. Delivers free ferric iron to the bloodstream after dissociation from the sucrose chain. Iron is endocytosed by reticuloendothelial cells (macrophages, hepatocytes) and incorporated into transferrin for transport to bone marrow. Facilitates rapid replenishment of iron stores and stimulates erythropoiesis, correcting anemia … Read more
Venlafaxine Venlafaxine is a selective serotonin‑norepinephrine reuptake inhibitor (SNRI) widely used to treat major depressive disorder and various anxiety disorders. Mechanism of Action Dual reuptake inhibition: Blocks the serotonin transporter (SERT) and, at therapeutic plasma concentrations, the norepinephrine transporter (NET). Free‑radical inhibition: In high‑dose therapy (≥225 mg daily) a weak serotonin‑releasing effect may enhance serotonergic tone. Pharmacodynamic … Read more
Venetoclax Venetoclax is a potent, orally administered pro‑drug that selectively inhibits the anti‑apoptotic protein BCL‑2. First approved for chronic lymphocytic leukemia (CLL) with 17p deletion, it is now broadly used for other BCL‑2‑dependent malignancies, such as acute myeloid leukemia (AML) and multiple myeloma. Mechanism of Action Venetoclax binds the BH3 pocket of BCL‑2 with high … Read more